Based on the aggregated intelligence of 180,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, British medical technology company Smith & Nephew (SNN 0.42%) has earned a coveted five-star ranking.
With that in mind, let's take a closer look at Smith & Nephew and see what CAPS investors are saying about the stock right now.
Smith & Nephew facts
|
Headquarters (founded) |
London (1856) |
|
Market Cap |
$9.8 billion |
|
Industry |
Health care equipment |
|
Trailing-12-Month Revenue |
$4.2 billion |
|
Management |
CEO Olivier Bohuon (since 2011) |
|
Return on Equity (average, past 3 years) |
23.1% |
|
Cash/Debt |
$445.0 million / $69.0 million |
|
Dividend Yield |
1.8% |
|
Competitors |
Johnson & Johnson (JNJ 0.14%) |
Sources: S&P Capital IQ and Motley Fool CAPS.
On CAPS, 92% of the 125 members who have rated Smith & Nephew believe the stock will outperform the S&P 500 going forward.
Just last week, one of those Fools, dreamjob, succinctly summed up the bull case for our community:
Management at [Smith & Nephew] has achieved very strong [return on invested capital] and Cash ROIC numbers. Sales, earnings, and book value are all growing at a healthy clip. There are positive, stable, and growing owner earnings and free cash flow. There is also manageable debt here. I believe this is priced slightly below intrinsic value. I also like that this has recently become a 5 Star CAPS stock.
If you want market-topping returns, you need to put together the best portfolio you can. Owning exceptional stocks is a surefire way to secure your financial future. Of course, despite its five-star rating, Smith & Nephew may not be your top choice.
Want to see how well (or not so well) the stocks in this series are performing? Follow the TrackPoisedTo CAPS account.
